MedTrace Logo

Abemaciclib in Treating Patients With Advanced, Refractory, and Unresectable Digestive System Neuroendocrine Tumors

NCT03891784 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2026-01-14

No results posted yet for this study

Summary

This phase II trial studies how well abemaciclib works in treating patients with digestive system neuroendocrine tumors that have spread to other places in the body, do not respond to treatment, and cannot be removed by surgery. Abemaciclib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Conditions

  • Advanced Digestive System Neuroendocrine Neoplasm
  • Digestive System Neuroendocrine Tumor
  • Foregut Neuroendocrine Tumor
  • Hindgut Neuroendocrine Tumor
  • Locally Advanced Unresectable Digestive System Neuroendocrine Neoplasm
  • Metastatic Digestive System Neuroendocrine Neoplasm
  • Midgut Neuroendocrine Tumor
  • Pancreatic Neuroendocrine Tumor
  • Refractory Digestive System Neuroendocrine Neoplasm

Interventions

DRUG

Abemaciclib

Given PO

Sponsors & Collaborators

Principal Investigators

  • David B. Zhen · Fred Hutch/University of Washington Cancer Consortium

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-10-31
Primary Completion
2025-11-01
Completion
2026-07-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03891784 on ClinicalTrials.gov